Contact
Leslie L. Citrome, M.D., M.P.H., is a distinguished life fellow of the American Psychiatric Association and a fellow of the American Society of Clinical Psychopharmacology, where he currently serves as immediate past president. He is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. In 2019, Dr. Citrome received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science)”. In 2018, 2021, and 2023, Dr. Citrome was recognized as the Voluntary Faculty Teacher of the Year in the Department of Psychiatry and Behavioral Sciences at New York Medical College/Westchester Medical Center.
Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of the number needed to treat and the number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australia. Dr. Citrome’s main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is an author and co-author of more than 600 research reports, reviews, and chapters in the scientific literature. He is a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; and also serves as an editorial board member for 11 other journals.
Education
- Residency, Psychiatry, New York University
- M.D., McGill University Faculty of Medicine
- M.P.H., Columbia University School of Public Health
- DEC, Pure and Applied Science, Dawson College
Areas of Expertise
- Mental Health Disorders
Publications
- Citrome L, Czobor P, Komaroff M, et. al. "The Clinically Meaningful Score Difference and Meaningful Score Regions in Positive and Negative Syndrome Scale Total Score from Post Hoc Analyses of a Phase 3 Pivotal Clinical Trial of Transdermal Asenapine in Patients with Schizophrenia." Neuropsychiatric disease and treatment, 22(), (2026) 562499. doi: 10.2147/NDT.S562499
- Kishi T, Citrome L, Sakuma K, et. al. "Relapse and its modifiers after antipsychotic discontinuation in first-episode non-affective psychosis: A systematic review and meta-analysis." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 109(), (2026) 112828. doi: 10.1016/j.euroneuro.2026.112828
- Goldberg JF, Swartz HA, McIntyre RS, et. al. "The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus." The British journal of psychiatry : the journal of mental science, (), (2026) 1-9. doi: 10.1192/bjp.2026.10580
- Goldberg JF, McIntyre RS, Swartz HA, et. al. "Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force." JAMA network open, 9(2), (2026) e260043. doi: 10.1001/jamanetworkopen.2026.0043
- Voegel A, Naranjo RR Jr, Diaz L, et. al. "Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States." Patient preference and adherence, 20(), (2026) 570441. doi: 10.2147/PPA.S570441
- Citrome L. "Introducing a special collection of CME articles about long-acting injectable antipsychotics." CNS spectrums, 30(S1), (2025) S43-S44. doi: 10.1017/S1092852925100722
- Citrome L. "What's in a name? What shall we call xanomeline-trospium combination?" Expert opinion on drug safety, (), (2025) 1-2. doi: 10.1080/14740338.2025.2588631
Memberships and Affiliations
- Distinguished Life Fellow of the American Psychiatric Association
- Fellow of the American Society of Clinical Psychopharmacology
- Fellow (Emeritus), Collegium Internationale Neuro-Psychopharmacologicum (CINP)
